目的研究交趾黄檀Dalbergia cochinchinensis Pierre ex Laness的新黄酮类成分及其抗H9c2心肌细胞缺氧/复氧损伤活性。方法交趾黄檀70%乙醇提取物采用硅胶、Sephadex LH-20、反相制备HPLC进行分离纯化,根据理化性质及波谱数据鉴定所得...目的研究交趾黄檀Dalbergia cochinchinensis Pierre ex Laness的新黄酮类成分及其抗H9c2心肌细胞缺氧/复氧损伤活性。方法交趾黄檀70%乙醇提取物采用硅胶、Sephadex LH-20、反相制备HPLC进行分离纯化,根据理化性质及波谱数据鉴定所得化合物的结构。采用CCK-8法检测其对H9c2心肌细胞的活性及对H9c2细胞缺氧/复氧损伤的保护作用,并分析其构效关系。结果从中分离得到12个化合物,分别鉴定为阔叶黄檀酚(1)、5-O-methyllatifolin(2)、mimosifoliol(3)、5-O-methydalbergiphenol(4)、dalbergiphenol(5)、cearoin(6)、2,4-dihydroxy-5-methoxy-benzophenone(7)、2-hydroxy-4,5-dimethoxybenzophenone(8)、melannoin(9)、2,2′,5-trihydroxy-4-methoxybenzophenone(10)、黄檀素(11)、4-甲氧基黄檀醌(12)。黄檀酚及黄檀内酯类化合物对H9c2细胞毒性较小,黄檀酚类化合物抗H9c2心肌细胞缺氧/复氧损伤活性较强。结论化合物8为新天然产物,化合物4、9为首次从该植物中分离得到。黄檀酚类化合物可能是抗H9c2细胞缺氧/复氧损伤的主要新黄酮类成分。展开更多
目的:对常规西药联合芪苈强心胶囊与单用西药治疗慢性心力衰竭的临床疗效进行比较,证明芪苈强心胶囊联合西药治疗更具优势,为慢性心衰的临床治疗策略提供参考依据。方法:检索PubMed、Embase、Web of science、中国知网(CNKI)、万方(WanF...目的:对常规西药联合芪苈强心胶囊与单用西药治疗慢性心力衰竭的临床疗效进行比较,证明芪苈强心胶囊联合西药治疗更具优势,为慢性心衰的临床治疗策略提供参考依据。方法:检索PubMed、Embase、Web of science、中国知网(CNKI)、万方(WanFang)、维普(VIP)、中国生物医学文献(CBM)等数据库中常规西药治疗以及西药联合芪苈强心胶囊治疗慢性心衰的随机对照实验(RCTs),采用Cochrance推荐的RCT的工具进行偏倚风险评估后,用Rev Man 5.4及Stata 17软件进行Meta分析。比较常规西药联合芪苈强心胶囊组(以下简称治疗组)与常规西药组(以下简称对照组)的心功能疗效评价、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、心脏每搏输出量(SV)、6 min步行试验(6MWT)距离及N末端脑钠肽前体(NT-proBNP)指数。结果:纳入符合标准的RCTs共20篇,包括2953例患者,其中治疗组1508例,对照组1445例。Meta分析结果显示,治疗组的心功能疗效评价、LVEF、LVEDD、SV、6MWT及NT-proBNP改善情况均显著优于对照组。其中心功能疗效评价(OR=2.09,95%CI:1.71~2.55,P<0.001)、LVEF(WMD=7.05,95%CI:5.30~8.79,P<0.00001)、LVEDD(WMD=6.73,95%CI:3.18~10.29,P=0.0002)、SV(WMD=6.73,95%CI:3.18~10.29,P=0.0002)、6MWT(SMD=0.70,95%CI:0.54~0.87,P<0.00001)、NT-proBNP(SMD=-1.95,95%CI:-2.52~-1.38,P<0.0001),差异均有统计学意义。结论:常规西药联合芪苈强心胶囊能显著提高心力衰竭的临床疗效,改善LVEF、LVEDD、SV及NT-proBNP指数,提高运动耐量,在治疗中值得借鉴。展开更多
Objective: To compare the clinical efficacy of conventional Western medicine combined with Qiliqiangxin capsule and western medicine alone in the treatment of chronic heart failure, and to prove that Qiliqiangxin caps...Objective: To compare the clinical efficacy of conventional Western medicine combined with Qiliqiangxin capsule and western medicine alone in the treatment of chronic heart failure, and to prove that Qiliqiangxin capsule combined treatment has more advantages, providing reference for clinical decision-making in the treatment of chronic heart failure. Methods: Randomized controlled trials (RCTs) of conventional Western medicine treatment and Western medicine combined with Qiliqiangxin capsule in the treatment of chronic heart failure were searched in databases such as PubMed, Embase, Webofscience, CNKI, WanFang, VIP, and CBM. The bias risk assessment was conducted using the RCT tool recommended by Cochrane, and then the meta-analysis was performed using RevMan5.4 and Stata17 software. Compare the efficacy evaluation of cardiac function, left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), cardiac stroke output (SV), 6-minute walking test (6MWT), and N-terminal proBNP in the conventional western medicine combined with Qiliqiangxin capsule group (hereinafter referred to as the treatment group) and the conventional western medicine group (hereinafter referred to as the control group). Results: A total of 20 RCTs meeting the criteria were included, including 2953 patients, including 1508 in the treatment group and 1445 in the control group. The results of meta-analysis showed that the treatment group had significantly better cardiac function evaluation, LVEF, LVEDD, SV, 6MWT, and NT-proBNP improvement than the control group. Its central functional efficacy evaluation (OR=2.09,95% CI: 1.71-2.55, P<0.001), LVEF (WMD=7.05,95% CI: 5.30-8.79, P<0.00001), LVEDD (WMD=6.73, 95% CI: 3.18-10.29, P=0.0002), SV (WMD=6.73, 95% CI: 3.18-10.29, P=0.0002), 6MWT (SMD=0.70,95% CI: 0.54-0.87, P<0.00001), NT-proBNP (SMD=-1.95,95% CI: -2.5 2 to 1.38 (P<0.0001), with statistically significant differences. Conclusion: Conventional western medicine combined with Qiliqiangxin capsule can significantly improve the clinical efficacy of heart failure, improve LVEF, LVEDD, SV, and NT-proBNP index, and improve exercise tolerance. It is worth using for reference in the treatment.展开更多
文摘目的研究交趾黄檀Dalbergia cochinchinensis Pierre ex Laness的新黄酮类成分及其抗H9c2心肌细胞缺氧/复氧损伤活性。方法交趾黄檀70%乙醇提取物采用硅胶、Sephadex LH-20、反相制备HPLC进行分离纯化,根据理化性质及波谱数据鉴定所得化合物的结构。采用CCK-8法检测其对H9c2心肌细胞的活性及对H9c2细胞缺氧/复氧损伤的保护作用,并分析其构效关系。结果从中分离得到12个化合物,分别鉴定为阔叶黄檀酚(1)、5-O-methyllatifolin(2)、mimosifoliol(3)、5-O-methydalbergiphenol(4)、dalbergiphenol(5)、cearoin(6)、2,4-dihydroxy-5-methoxy-benzophenone(7)、2-hydroxy-4,5-dimethoxybenzophenone(8)、melannoin(9)、2,2′,5-trihydroxy-4-methoxybenzophenone(10)、黄檀素(11)、4-甲氧基黄檀醌(12)。黄檀酚及黄檀内酯类化合物对H9c2细胞毒性较小,黄檀酚类化合物抗H9c2心肌细胞缺氧/复氧损伤活性较强。结论化合物8为新天然产物,化合物4、9为首次从该植物中分离得到。黄檀酚类化合物可能是抗H9c2细胞缺氧/复氧损伤的主要新黄酮类成分。
文摘目的:对常规西药联合芪苈强心胶囊与单用西药治疗慢性心力衰竭的临床疗效进行比较,证明芪苈强心胶囊联合西药治疗更具优势,为慢性心衰的临床治疗策略提供参考依据。方法:检索PubMed、Embase、Web of science、中国知网(CNKI)、万方(WanFang)、维普(VIP)、中国生物医学文献(CBM)等数据库中常规西药治疗以及西药联合芪苈强心胶囊治疗慢性心衰的随机对照实验(RCTs),采用Cochrance推荐的RCT的工具进行偏倚风险评估后,用Rev Man 5.4及Stata 17软件进行Meta分析。比较常规西药联合芪苈强心胶囊组(以下简称治疗组)与常规西药组(以下简称对照组)的心功能疗效评价、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、心脏每搏输出量(SV)、6 min步行试验(6MWT)距离及N末端脑钠肽前体(NT-proBNP)指数。结果:纳入符合标准的RCTs共20篇,包括2953例患者,其中治疗组1508例,对照组1445例。Meta分析结果显示,治疗组的心功能疗效评价、LVEF、LVEDD、SV、6MWT及NT-proBNP改善情况均显著优于对照组。其中心功能疗效评价(OR=2.09,95%CI:1.71~2.55,P<0.001)、LVEF(WMD=7.05,95%CI:5.30~8.79,P<0.00001)、LVEDD(WMD=6.73,95%CI:3.18~10.29,P=0.0002)、SV(WMD=6.73,95%CI:3.18~10.29,P=0.0002)、6MWT(SMD=0.70,95%CI:0.54~0.87,P<0.00001)、NT-proBNP(SMD=-1.95,95%CI:-2.52~-1.38,P<0.0001),差异均有统计学意义。结论:常规西药联合芪苈强心胶囊能显著提高心力衰竭的临床疗效,改善LVEF、LVEDD、SV及NT-proBNP指数,提高运动耐量,在治疗中值得借鉴。
基金National Natural Science Foundation of China Regional Science Foundation Project(No.82160887)General Project of Guangxi Natural Science Foundation(No.2021GXNSFAA220111)Guangxi Natural Science Foundation Project Youth Science Foundation Project(No.2021GXNSFBA196018)。
文摘Objective: To compare the clinical efficacy of conventional Western medicine combined with Qiliqiangxin capsule and western medicine alone in the treatment of chronic heart failure, and to prove that Qiliqiangxin capsule combined treatment has more advantages, providing reference for clinical decision-making in the treatment of chronic heart failure. Methods: Randomized controlled trials (RCTs) of conventional Western medicine treatment and Western medicine combined with Qiliqiangxin capsule in the treatment of chronic heart failure were searched in databases such as PubMed, Embase, Webofscience, CNKI, WanFang, VIP, and CBM. The bias risk assessment was conducted using the RCT tool recommended by Cochrane, and then the meta-analysis was performed using RevMan5.4 and Stata17 software. Compare the efficacy evaluation of cardiac function, left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), cardiac stroke output (SV), 6-minute walking test (6MWT), and N-terminal proBNP in the conventional western medicine combined with Qiliqiangxin capsule group (hereinafter referred to as the treatment group) and the conventional western medicine group (hereinafter referred to as the control group). Results: A total of 20 RCTs meeting the criteria were included, including 2953 patients, including 1508 in the treatment group and 1445 in the control group. The results of meta-analysis showed that the treatment group had significantly better cardiac function evaluation, LVEF, LVEDD, SV, 6MWT, and NT-proBNP improvement than the control group. Its central functional efficacy evaluation (OR=2.09,95% CI: 1.71-2.55, P<0.001), LVEF (WMD=7.05,95% CI: 5.30-8.79, P<0.00001), LVEDD (WMD=6.73, 95% CI: 3.18-10.29, P=0.0002), SV (WMD=6.73, 95% CI: 3.18-10.29, P=0.0002), 6MWT (SMD=0.70,95% CI: 0.54-0.87, P<0.00001), NT-proBNP (SMD=-1.95,95% CI: -2.5 2 to 1.38 (P<0.0001), with statistically significant differences. Conclusion: Conventional western medicine combined with Qiliqiangxin capsule can significantly improve the clinical efficacy of heart failure, improve LVEF, LVEDD, SV, and NT-proBNP index, and improve exercise tolerance. It is worth using for reference in the treatment.